{"id":"NCT02373813","sponsor":"Amgen","briefTitle":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","officialTitle":"A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-20","primaryCompletion":"2019-12-06","completion":"2019-12-06","firstPosted":"2015-02-27","resultsPosted":"2020-12-19","lastUpdate":"2023-01-11"},"enrollment":371,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"etanercept pre-filled syringe subcutaneous injection","otherNames":["Enbrel","AMG916"]},{"type":"DRUG","name":"Oral methotrexate","otherNames":[]},{"type":"DRUG","name":"Placebo for etanercept subcutaneous injection","otherNames":[]},{"type":"DRUG","name":"Placebo for methotrexate","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Folic acid (non-investigational product)","otherNames":[]}],"arms":[{"label":"Open Label Run-In: Etanercept plus Methotrexate","type":"EXPERIMENTAL"},{"label":"Double-Blind Treatment: Methotrexate Monotherapy","type":"EXPERIMENTAL"},{"label":"Double-Blind Treatment: Etanercept Monotherapy","type":"EXPERIMENTAL"},{"label":"Double-Blind Treatment: Etanercept plus Methotrexate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to methotrexate monotherapy on maintenance of remission in participants with rheumatoid arthritis (RA) who were on etanercept plus methotrexate therapy.\n\nThis is a multicenter, randomized withdrawal, double-blind controlled study in participants with rheumatoid arthritis on etanercept plus methotrexate therapy who are in very good disease control for 6 months prior to study entry. The study will consist of a 30-day screening period, a 24-week open label run-in period, a 48-week double-blind treatment period and a 30-day safety follow-up period.","primaryOutcome":{"measure":"Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission (â‰¤ 3.3) at Week 48: Etanercept Monotherapy vs. Methotrexate Monotherapy","timeFrame":"Week 48","effectByArm":[{"arm":"Double-Blind Treatment: Methotrexate Monotherapy","deltaMin":28.7,"sd":null},{"arm":"Double-Blind Treatment: Etanercept Monotherapy","deltaMin":49.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":136,"countries":["United States","Argentina","Bulgaria","Canada","Czechia","France","Germany","Greece","Hungary","Italy","Mexico","Poland","Portugal","South Africa","Spain"]},"refs":{"pmids":["29224127","33205906","36459119","37061234"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":368},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Bronchitis"]}}